Guided Therapeutics GTHP

OTC GTHP
$0.10 -0.01 (-9.09%)
At close: Nov 11, 2026 · 4:00 PM EST

Guided Therapeutics (GTHP) stock price is $0.10, down 9.09% on the day, as of Nov 11, 2026. It has a market cap of $10.62K, and is classified in the Medical Devices industry (Healthcare sector).

Key Stats
Market Cap10,618.96
P/E0.00
FCF (Yr)-1.07 Mn
ROA (Yr)-236.57
EV to EBIT0.26
Net Income (Yr)-3.20 Mn
Enterprise Value-520,381.04
Add ratio to table…

About

Guided Therapeutics, Inc. is a medical technology company focused on developing innovative medical devices that improve healthcare. Its primary product is the LuViva Advanced Cervical Scan, a noninvasive cervical cancer detection device that uses biophotonics to scan the cervix with light and analyze reflected and fluorescent light. The device is designed to identify cervical cancers and precancers painlessly and at the point of care, offering a rapid alternative to…

Read more ↓
Sector: Healthcare Sector rationale The company designs and manufactures the LuViva Advanced Cervical Scan, a medical device used for cervical cancer detection, and sells single-use disposable cervical guides. Its revenue is derived from selling these medical products to distributors, hospitals, and government health programs, which falls squarely within the Medical Devices industry of the Healthcare sector. Industries: Medical Devices Medical Devices Primary Guided Therapeutics designs and manufactures the LuViva Advanced Cervical Scan, a medical device used for the noninvasive detection of cervical cancer. The company generates revenue from the sale of these therapeutic/diagnostic systems to distributors and government health programs. Medical Supplies Medical Supplies Secondary The company sells single-use disposable cervical guides that accompany the LuViva systems, which are medical consumables/supplies. Classified using BQ-MICS CIK: 0000924515

Product and Service Breakdown of Revenue (2020)

History

Statement Geographical Breakdown of Revenue (2020)

History
Peer percentiles

How Guided Therapeutics ranks

Ranked against the 250 companies in Medical Devices and Diagnostics58 metrics · as of Nov 11, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last
  • P/ENegative earnings 0.00xMedian 26.3x 1st
  • P/FCFNegative free cash flow −0.01xMedian 25.8x 1st
  • P/Operating cash flowNegative operating cash flow −0.01xMedian 21.4x 1st
  • P/S 0.02xMedian 2.85x 99th
  • P/BNegative shareholder equity 0.00xMedian 2.47x Not meaningful —
  • P/Tangible bookNegative tangible equity 0.00xMedian 3.15x Not meaningful —
  • EV/EBITDANegative EBITDA −0.20xMedian 18.3x 3rd
  • EV/EBITNegative EBIT −0.18xMedian 28.0x 4th
  • EV/Revenue 0.54xMedian 3.08x 89th
  • EV/FCFNegative free cash flow −0.23xMedian 29.7x 5th
  • EV/Operating cash flowNegative operating cash flow −0.23xMedian 22.1x 4th
  • PEG (3Y EPS CAGR)Negative earnings 0.00Median 0.96 Not meaningful —
Peer group

Peer Comparison

Companies in the Medical Devices
View all peers
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 TMO Thermo Fisher Scientific Inc. 266.22 Bn37.595.6241.37 Bn
2 ABT Abbott Laboratories 191.31 Bn40.753.9731.16 Bn
3 DHR Danaher Corp /De/ 166.16 Bn38.396.4926.48 Bn
4 ISRG Intuitive Surgical Inc 155.98 Bn53.1113.47-
5 MDT Medtronic plc 130.05 Bn14.863.5128.15 Bn
6 SYK Stryker Corp 123.40 Bn34.204.6914.93 Bn
7 BSX Boston Scientific Corp 64.81 Bn18.503.0811.95 Bn
8 GTHP Guided Therapeutics Inc 0.00 Bn0.000.020.00 Bn